drugset / Trial / NCT00034138
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will compare the pharmacokinetic profile of OvaRex MAb-B43.13 ascites fluid product and OvaRex MAb-B43.13 cell culture product. Safety and immune responses following treatment with the cell culture product will be evaluated.
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oregovomab | Monoclonal antibody | 2 mg | — |